



25th December, 2025

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1
G Block, Bandra-Kurla Complex, Bandra (E)
Mumbai — 400051

Scrip Symbol : CURIS

Dear Sir/Mam,

Sub.: Outcome of Board Meeting

Ref.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 regarding Joint Venture Agreement entered with M/s. Eurosun Pharmaceuticals.

Dear Sir / Madam,

This is to inform you that in the board meeting held on 24th December, 2025 at the registered office of the company, Board has entered into Joint Venture Agreement with M/s. Eurosun Pharmaceuticals to act as exclusive exporter and distributor of Pharmaceutical products manufactured by Curis Lifesciences Limited in Nigeria.

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we hereby inform you that, the Company has executed a joint venture agreement with M/s. Eurosun Pharmaceuticals to act as exclusive exporter and distributor of Pharmaceutical products manufactured by Curis Lifesciences Limited in Nigeria, whereby M/s. Eurosun Pharmaceuticals will handle product export, regulatory approvals and market development in Nigeria.

In this regard, details as required under Regulation 30 of the SEBI LODR Regulations read are enclosed as Annexure-A.

We request you to kindly take this on record. Thanking you

FOR CURIS LIFESCIENCES LIMITED

JAIMIK MANSUKHLAL PATEL
WHOLE-TIME DIRECTOR
DIN: 07371003



Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr no.	Particulars	Description
1.	Name(s) of parties with whom the agreement is entered	M/s. Eurosun Pharmaceuticals
2.	Purpose of entering into the agreement	Exclusive Manufacturing and Export Agreement in form of Joint Venture in the Federal Republic of Nigeria.
3.	Shareholding, if any, in the entity with whom the agreement is executed	Curis Lifesciences Limited does not hold any shares in M/s. Eurosun Pharmaceuticals
4.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	<ul style="list-style-type: none">M/s. Eurosun Pharmaceuticals is appointed as the exclusive exporter and distributor of pharmaceutical products manufactured by Curis Lifesciences Limited in the Federal Republic of Nigeria.Both parties agree not to engage with other partners for the specified products within the Nigerian territory.Net profit or loss from Nigerian operations shall be split equally (50:50)
5.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	M/s. Eurosun Pharmaceuticals is not related to promoter/promoter group/ group companies in any manner
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length	<p>No, the transaction does not fall within the ambit of related party transaction.</p> <p>But, the commercial structure of the transaction deviates from standard market practices as our Company provides products based on an "Open Cost Sheet" (covering RM, PM, and process costs) without adding a standard manufacturer's profit margin at the billing stage, and the parties have agreed to a 50:50 profit/loss sharing ratio on the final net realization from the Nigerian market. By sharing the risk of loss and the reward of profit equally, the transaction functions more like a Joint Venture or Partnership rather than a standard commercial sale.</p> <p>Accordingly, even though the transaction does not fall within the ambit of "Related Party Transactions" under statutory definitions, it is not conducted on an arm's length basis.</p>
7.	In case of issuance of shares to the parties, details of issue price, class of shares issued	No shares issued
8.	Any other disclosures related to such agreements, viz., details of nominee on the	No nominees placed on the Board of Listed Entity



	board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc	
9.	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	This is not case of Termination or amendment of agreement.